Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Eloralintide once weekly was well tolerated with minimal gastrointestinal adverse events and resulted in clinically meaningful weight loss.
Authors
- Daniel A. Briere
- AXEL HAUPT
- Kieren J. Mather (ORCID: https://orcid.org/0000-0001-8696-7500)
- Hongchang Qu (ORCID: https://orcid.org/0000-0002-9835-3503)
- Edward Pratt (ORCID: https://orcid.org/0000-0003-4449-6231)
- Hilda Ibriga
- Shobha Bhattachar
- Beth Tidemann‐Miller
- Lai San Tham
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1111/dom.70439
- Citations
- 1
- Primary Topic
- Adipose Tissue and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 32.84
Funders
- Eli Lilly and Company